Drug intelligence / Profile preview

VE-4062

Development stage: Preclinical
Lead developer: Verseon
Modality: Small Molecules
Administration: Oral

Overview

VE-4062 is an investigational oral small molecule plasma kallikrein inhibitor developed by Verseon. It is currently in preclinical development as a potential treatment for hereditary angioedema (HAE). The drug is designed to block the activity of plasma kallikrein, thereby reducing bradykinin levels and preventing swelling attacks associated with HAE. Its oral administration aims to offer a more convenient prophylactic treatment option compared to existing injectable or infusible therapies.

Targets

KLKB1 (Plasma kallikrein)

Beyond the preview

Go deeper on VE-4062.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VE-4062.

Explore the full profile